Patients had numerically better but statistically similar five-year overall survival rates for IMRT (30.8 per cent) compared to 3D-CRT (26.6 per...
Vous n'êtes pas connecté
MONDAY, July 1, 2024 -- For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line treatment, according to a study published...
Patients had numerically better but statistically similar five-year overall survival rates for IMRT (30.8 per cent) compared to 3D-CRT (26.6 per...
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be...
An analysis of data from a randomised clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib,...
FRIDAY, June 28, 2024 -- For patients with early-stage cervical cancer, disease-free and overall survival are lower for patients undergoing minimally...
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with...
A new study published in JAMA Network Open by an international cohort of researchers provides the latest data on the effectiveness of treating...
DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Insight 2024” report provides comprehensive...
WEDNESDAY, July 3, 2024 -- The Mediterranean diet can help cancer survivors maintain their heart health and live longer, a new study says. Cancer...
MONDAY, July 1, 2024 -- Among patients with incompletely excised basal cell carcinoma (BCC), only about 16 percent with positive histopathologic...
WEDNESDAY, July 3, 2024 -- For patients with refractory gastroesophageal reflux disease (GERD), those receiving antireflux mucosectomy (ARMS) have a...